This study will compare the efficacy and safety of the two 11β-hydroxylase inhibitors-metyrapone and osilodrostat-in patients with MACS. Primary outcome To compare the efficacy (biochemical and clinical) of the two 11β-hydroxylase inhibitors (CYP11B1), metyrapone and osilodrostat, in patients with MACS not treated surgically (mainly bilateral adenomas or adrenal hyperplasias), as well as their side effects at time 0-, 3- and 6-months post-treatment. Secondary outcome To evaluate alterations in clinical parameters (Blood Pressure, Body Mass Index-BMI), metabolic parameters (fasting blood glucose, insulin, Hb1Ac, HOMA, OGTT and lipids levels) at time 0-, 3- and 6-month after the initiation of the treatment and their effect on Bone Mineral Density (BMD) 1 year post-diagnosis
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Comparison of the efficacy of metyrapone and osilodrostat
Timeframe: Baseline ( at t=0), at t=3 months and at =6 months
Comparison of the efficacy of metyrapone and osilodristat
Timeframe: Baseline (at t= 0), at t= 3 months and t= 6 months
Comparison of the efficacy of metyrapone and osilodristat
Timeframe: Baseline ( at t=0), at t=3 months and at t=6 months
Comparison of the efficacy of metyrapone and osilodristat
Timeframe: Baseline ( at t=0), at t=3 months and at =6 months
Comparison of metyrapone and osilodrostat efficacy
Timeframe: Baseline (at t=0), at t=3 months , at t =6 months
Comparison of metyrapone and osilodrostat in terms of alterations of metabolic parameters
Timeframe: Baseline (t=0), at t= 3months, at t=6 months